ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
fluffington
|
451 |
139K |
1 |
28/03/24 |
28/03/24 |
ASX - By Stock
|
451
|
139K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
fluffington
|
510 |
148K |
1 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
510
|
148K
|
1
|
|
ASX - By Stock
|
ZIP |
Re:
$2 PARTY
|
|
fluffington
|
2.6K |
526K |
2 |
08/03/24 |
08/03/24 |
ASX - By Stock
|
2.6K
|
526K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Half Year Financial Results Presentation
|
|
fluffington
|
78 |
23K |
5 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
78
|
23K
|
5
|
|
ASX - By Stock
|
BIT |
Re:
Ann: Half Yearly Report and Accounts
|
|
fluffington
|
147 |
31K |
5 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
147
|
31K
|
5
|
|
ASX - By Stock
|
ZIP |
Re:
$2 PARTY
|
|
fluffington
|
2.6K |
526K |
12 |
09/02/24 |
09/02/24 |
ASX - By Stock
|
2.6K
|
526K
|
12
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
fluffington
|
102 |
37K |
7 |
31/01/24 |
31/01/24 |
ASX - By Stock
|
102
|
37K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading Halt
|
|
fluffington
|
716 |
197K |
2 |
21/12/23 |
21/12/23 |
ASX - By Stock
|
716
|
197K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Entitlement Offer and Placement Investor Presentation
|
|
fluffington
|
48 |
15K |
9 |
04/12/23 |
04/12/23 |
ASX - By Stock
|
48
|
15K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading Halt
|
|
fluffington
|
716 |
197K |
1 |
01/12/23 |
01/12/23 |
ASX - By Stock
|
716
|
197K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading Halt
|
|
fluffington
|
716 |
197K |
11 |
01/12/23 |
01/12/23 |
ASX - By Stock
|
716
|
197K
|
11
|
|
ASX - By Stock
|
BIT |
Re:
Ann: Presentation to Annual General Meeting
|
|
fluffington
|
62 |
18K |
10 |
22/11/23 |
22/11/23 |
ASX - By Stock
|
62
|
18K
|
10
|
|
ASX - By Stock
|
MSB |
Re:
2023 The Final Countdown
|
|
fluffington
|
3.4K |
1.1M |
6 |
06/09/23 |
06/09/23 |
ASX - By Stock
|
3.4K
|
1.1M
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Change in substantial holding
|
|
fluffington
|
38 |
15K |
16 |
29/08/23 |
29/08/23 |
ASX - By Stock
|
38
|
15K
|
16
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Change in substantial holding
|
|
fluffington
|
38 |
15K |
7 |
29/08/23 |
29/08/23 |
ASX - By Stock
|
38
|
15K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
2023 Next Steps
|
|
fluffington
|
165 |
65K |
12 |
18/08/23 |
18/08/23 |
ASX - By Stock
|
165
|
65K
|
12
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading Halt
|
|
fluffington
|
1.3K |
540K |
28 |
03/08/23 |
03/08/23 |
ASX - By Stock
|
1.3K
|
540K
|
28
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
fluffington
|
17K |
6.5M |
19 |
28/07/23 |
28/07/23 |
ASX - By Stock
|
17K
|
6.5M
|
19
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MESO watch and banter
|
|
fluffington
|
400 |
147K |
3 |
25/07/23 |
25/07/23 |
ASX - By Stock
|
400
|
147K
|
3
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MESO watch and banter
|
|
fluffington
|
400 |
147K |
11 |
25/07/23 |
25/07/23 |
ASX - By Stock
|
400
|
147K
|
11
|
|
ASX - By Stock
|
MSB |
Re:
ODAC August 2020 event materials
|
|
fluffington
|
85 |
25K |
10 |
20/07/23 |
20/07/23 |
ASX - By Stock
|
85
|
25K
|
10
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MESO watch and banter
|
|
fluffington
|
400 |
147K |
14 |
18/07/23 |
18/07/23 |
ASX - By Stock
|
400
|
147K
|
14
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
fluffington
|
207 |
60K |
4 |
03/05/23 |
03/05/23 |
ASX - By Stock
|
207
|
60K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
fluffington
|
207 |
60K |
8 |
28/04/23 |
28/04/23 |
ASX - By Stock
|
207
|
60K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Schedules GvHD Pre-License Manufacturing Inspection
|
|
fluffington
|
275 |
110K |
13 |
22/03/23 |
22/03/23 |
ASX - By Stock
|
275
|
110K
|
13
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L
|
|
fluffington
|
1.0K |
380K |
9 |
09/03/23 |
09/03/23 |
ASX - By Stock
|
1.0K
|
380K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Pause in Trading
|
|
fluffington
|
74 |
28K |
3 |
08/03/23 |
08/03/23 |
ASX - By Stock
|
74
|
28K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Pause in Trading
|
|
fluffington
|
74 |
28K |
6 |
08/03/23 |
08/03/23 |
ASX - By Stock
|
74
|
28K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Remestemcel Clinical and Potency Studies Presented at Tandem
|
|
fluffington
|
217 |
69K |
8 |
07/03/23 |
07/03/23 |
ASX - By Stock
|
217
|
69K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Remestemcel Clinical and Potency Studies Presented at Tandem
|
|
fluffington
|
217 |
69K |
8 |
07/03/23 |
07/03/23 |
ASX - By Stock
|
217
|
69K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Remestemcel Clinical and Potency Studies Presented at Tandem
|
|
fluffington
|
217 |
69K |
8 |
07/03/23 |
07/03/23 |
ASX - By Stock
|
217
|
69K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
fluffington
|
17K |
6.5M |
6 |
28/02/23 |
28/02/23 |
ASX - By Stock
|
17K
|
6.5M
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Breakout
|
|
fluffington
|
144 |
47K |
4 |
09/02/23 |
09/02/23 |
ASX - By Stock
|
144
|
47K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
fluffington
|
17K |
6.5M |
3 |
21/01/23 |
21/01/23 |
ASX - By Stock
|
17K
|
6.5M
|
3
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2022, The TurnAround
|
|
fluffington
|
1.0K |
319K |
5 |
30/11/22 |
30/11/22 |
ASX - By Stock
|
1.0K
|
319K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2022, The TurnAround
|
|
fluffington
|
1.0K |
319K |
3 |
30/11/22 |
30/11/22 |
ASX - By Stock
|
1.0K
|
319K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2022, The TurnAround
|
|
fluffington
|
1.0K |
319K |
7 |
30/11/22 |
30/11/22 |
ASX - By Stock
|
1.0K
|
319K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
fluffington
|
4.8K |
2.3M |
0 |
12/11/22 |
12/11/22 |
ASX - By Stock
|
4.8K
|
2.3M
|
0
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
fluffington
|
9.3K |
2.6M |
1 |
31/10/22 |
31/10/22 |
ASX - By Stock
|
9.3K
|
2.6M
|
1
|
|
ASX - By Stock
|
BIT |
Re:
chart daily
|
|
fluffington
|
3.2K |
1.0M |
3 |
05/08/22 |
05/08/22 |
ASX - By Stock
|
3.2K
|
1.0M
|
3
|
|
ASX - By Stock
|
BIT |
Re:
Scripps Research study identifies existing drugs as potential COVID-19 therapies
|
|
fluffington
|
171 |
49K |
2 |
05/08/22 |
05/08/22 |
ASX - By Stock
|
171
|
49K
|
2
|
|
ASX - By Stock
|
BIT |
Re:
Ann: POSITIVE FDA GUIDANCE FOR COVID-19 CLINICAL PROGRAM
|
|
fluffington
|
472 |
180K |
2 |
08/07/22 |
08/07/22 |
ASX - By Stock
|
472
|
180K
|
2
|
|
ASX - By Stock
|
BIT |
Re:
Ann: POSITIVE FDA GUIDANCE FOR COVID-19 CLINICAL PROGRAM
|
|
fluffington
|
472 |
180K |
5 |
06/07/22 |
06/07/22 |
ASX - By Stock
|
472
|
180K
|
5
|
|
ASX - By Stock
|
BIT |
Re:
Ann: POSITIVE FDA GUIDANCE FOR COVID-19 CLINICAL PROGRAM
|
|
fluffington
|
472 |
180K |
1 |
30/05/22 |
30/05/22 |
ASX - By Stock
|
472
|
180K
|
1
|
|
ASX - By Stock
|
BIT |
Re:
Ann: POSITIVE FDA GUIDANCE FOR COVID-19 CLINICAL PROGRAM
|
|
fluffington
|
472 |
180K |
2 |
30/05/22 |
30/05/22 |
ASX - By Stock
|
472
|
180K
|
2
|
|
ASX - By Stock
|
BIT |
Re:
Ann: POSITIVE FDA GUIDANCE FOR COVID-19 CLINICAL PROGRAM
|
|
fluffington
|
472 |
180K |
2 |
30/05/22 |
30/05/22 |
ASX - By Stock
|
472
|
180K
|
2
|
|
ASX - By Stock
|
BIT |
Re:
$10 Billion Deal
|
|
fluffington
|
12K |
6.1M |
1 |
27/05/22 |
27/05/22 |
ASX - By Stock
|
12K
|
6.1M
|
1
|
|
ASX - By Stock
|
BIT |
Re:
$10 Billion Deal
|
|
fluffington
|
12K |
6.1M |
6 |
27/05/22 |
27/05/22 |
ASX - By Stock
|
12K
|
6.1M
|
6
|
|
ASX - By Stock
|
BIT |
Re:
$10 Billion Deal
|
|
fluffington
|
12K |
6.1M |
5 |
27/05/22 |
27/05/22 |
ASX - By Stock
|
12K
|
6.1M
|
5
|
|
ASX - By Stock
|
BIT |
Re:
$10 Billion Deal
|
|
fluffington
|
12K |
6.1M |
3 |
26/05/22 |
26/05/22 |
ASX - By Stock
|
12K
|
6.1M
|
3
|
|